Revenue segments as reported by the company.

Nutrition

Diagnostics

Established Pharmaceuticals

Medical Devices

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Amortization of intangible assets

Research and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Abbott Labs

St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.

St. Jude Medical

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Abbott Labs reports solid Q4 performance and eyes growth opportunities

Abbott Labs delivered a strong performance in Q4 2022, showcasing resilience and strategic focus amidst challenges in certain business segments.
The company's emphasis on innovation, product excellence, and market expansion positions it well for future growth and success.
While facing challenges like inflation and market restrictions, Abbott is actively pursuing opportunities for growth through new product launches and strategic investments.
Investors can be optimistic about Abbott's outlook for 2023, with a positive trajectory in sales, product development, and cash use priorities.

Abbott Labs surpasses Q1 earnings estimates, eyes growth opportunities

Abbott Labs exceeded earnings expectations with strong organic sales growth. Performance driven by Medical Devices, Established Pharmaceuticals, and Nutrition segments. Challenges include lower Diagnostics sales and uncertainties around COVID testing.

Abbott Labs excels in Q2 with strong sales growth and innovation

Abbott Labs delivered a strong performance in Q2 2023, driven by robust organic sales growth, successful product launches, and strategic market expansion initiatives across key business segments.
Despite challenges related to COVID testing demand decline and exchange rate impacts, Abbott's focus on innovation, market share recovery, and operational efficiency positions it well for sustained growth and profitability.
The company's strengths in diverse product offerings, market leadership in key segments, and opportunities for further expansion and innovation underscore its resilience and strategic vision in the healthcare industry.
By navigating challenges, leveraging strengths, and capitalizing on opportunities, Abbott is poised to maintain its growth trajectory, drive market leadership, and deliver value to shareholders and stakeholders.

Abbott Labs excels in Q3, eyes growth in China and innovation

Abbott Labs delivered robust performance across key segments, positioning well for sustained growth.
The company showcased strong sales growth, user adoption, and strategic readiness for future opportunities.
While challenges exist in market dynamics and cost management, Abbott remains optimistic about its outlook.
Overall, Abbott's Q3 results reflect a resilient business model and a focus on innovation and growth.

Abbott Labs surpasses 2023 expectations, poised for strong 2024 growth

Abbott Labs delivered impressive performance in 2023, exceeding expectations and showcasing strength across key segments. The company's diversified business model and strategic investments position it well for continued growth in 2024. Abbott's focus on sustainable growth, market share expansion, and innovation bode well for its future.

Abbott Labs excels in Q1, raises guidance on strong performance

Abbott Labs delivered a standout quarter with robust financial performance, strategic product launches, and optimistic guidance updates. Despite facing FX challenges, the company remains well-positioned for growth through innovation and market expansion.

Abbott Labs excels in Q2, raises guidance amid strong segment performance

Abbott Labs' Q2 performance reflects strong growth momentum across segments and strategic focus on innovation and market expansion.
The company's strengths in Nutrition, Diagnostics, and Medical Devices position it well for sustained growth and value creation.
While facing challenges such as ongoing litigation, Abbott Labs remains poised to capitalize on opportunities in biosimilars, new product approvals, and market expansion.

Abbott Labs excels in Q3 with strong sales growth and strategic advancements

Abbott Labs demonstrated robust financial performance and strategic advancements in Q3 2024, showcasing resilience and innovation. While facing potential challenges ahead, the company's diverse portfolio and market-leading products position it well for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Abbott's Assert-IQ offers the world's longest battery life† for an insertable cardiac monitor (ICM) The latest addition to Abbott's portfolio of connected health devices, the Assert-IQ ICM offers long-term monitoring and remote programming to improve connectivity to patients The device provides continuous monitoring for abnormal heart rhythms while offering tools designed to help improve data management and workflow within a physician's practice ABBOTT PARK, Ill., May 18, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced its Assert-IQ™ insertable cardiac monitor (ICM) has received U.S. Food and Drug Administration (FDA) clearance, giving physicians a new option for diagnostic evaluation and long-term monitoring of people experiencing irregular heartbeats.

Abbott Receives FDA Clearance for Assert-IQ™ Insertable Cardiac Monitor to Help Doctors Monitor People's Heart Rhythms Long-Term

FDA approval was backed by Abbott's DISTINCT study, the largest randomized controlled trial for spinal cord stimulation (SCS) in people with chronic back pain when surgery is not an option Results for the first 200 patients demonstrated that people who used the company's SCS products experienced significant relief and improvements in pain, function, quality of life and psychological status1,2 Prior to enrollment in the study, participants suffered from severe, disabling chronic back pain for an average of 12.8 years2 ABBOTT PARK, Ill., May 16, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved its spinal cord stimulation (SCS) devices for the treatment of chronic back pain in people who have not had or are not eligible to receive back surgery, known as non-surgical back pain.

Abbott Receives FDA Approval for Its Spinal Cord Stimulation Systems to Treat Chronic Back Pain in People Who Have Limited Surgical Options

Abbott's (ABT) latest additions to Diversity in Clinical Trials effort expand upon the alliances, awards and the emphasis on diverse participation in its own clinical trials.

Abbott's (ABT) New Pact to Advance Clinical Trials Diversity

Intuitive Surgical

There is more to the comparison, and in the sections below, we discuss why we believe ISRG stock will offer higher returns than ABT stock in the next three years.

Which Healthcare Stock Is A Better Pick: Abbott Or This Robotic Products Company?

Lowe's

PepsiCo

Target

American States Water

Johnson & Johnson

Realty Income Corp

Warren Buffett is credited with saying that his preferred length of time for owning a stock is forever. To give credit where credit is due, the Oracle of Omaha does put his money where his mouth is.

Investing for the Long-Term? Here are 7 Must-Have Dividend Stocks

New efforts focus on research infrastructure, continued training of diverse clinical research personnel and improved diversity within Abbott's own clinical trials Abbott's Diversity in Clinical Trials initiative aligns with the company's continued focus for greater health equity, expanded access, affordability and removing barriers to life-saving technology and innovation The new programs build on a successful first year of the multi-million-dollar corporate initiative ABBOTT PARK, Ill., May 11, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a series of new programs within its multi-million-dollar initiative to increase diversity in clinical trials and improve care among under-represented populations.

Abbott Announces New Partnerships and Programs to Advance its Diversity in Clinical Trials Initiative

Investors are optimistic about Abbott (ABT) on continued growth in the core Diagnostics arm.

Here's Why You Should Retain Abbott (ABT) Stock For Now

Cummins

Campbell Soup

General Electric

KB Home

Lennar

Medtronic

NVIDIA

Doing your homework on a company instead of listening to macro strategists is the best way to pick a winner, Cramer argues.

A number of outperforming stocks have bucked macro trends, Jim Cramer says

Abbott (ABT) continues to make good progress, increasing manufacturing production and recovering market share in the Nutrition business.

Abbott (ABT) EPD Business Grows Strong, Macro Issues Stay

Walgreens

Sharply rising payout ratios and negative payout ratios are both big red flags. The slowing or pausing of annual dividend growth is a major warning sign.

3 Dividend Stock Warning Signs That Could Portend Trouble

Exxon Mobil

High Inflation combined with low economic growth creates a period of stagflation, but these stocks can still outperform. All 3 of these dividend stocks have paid a growing dividend for 25+ CONSECUTIVE years.

3 Dividend Aristocrats To Help Beat Stagflation

Accenture Plc

AGCO

Arthur J. Gallagher & Co.

Clorox

ConocoPhillips

Carlisle Companies

Coterra Energy

D.R. Horton

Dick's Sporting Goods

EOG Resources

Expeditors International of Washington

Marsh & McLennan

Owens Corning

SAP SE

Steel Dynamics

Stryker

Tractor Supply

Visa

We explain why selling cash-covered puts and covered calls are relatively safe choices for earning a high income. We will discuss how to formulate an options income strategy that's sustainable and repeatable.

Earn Double-Digit Income With Options (May 2023)

Abbott and Target are both Dividend Kings, so they've shown that increasing dividends is important to them. These stocks also have what it takes to deliver earnings growth over time.

Got $1,000? 2 Top Dividend Stocks to Buy Now

ABBOTT PARK, Ill., April 27, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has completed the acquisition of Cardiovascular Systems, Inc. (CSI), a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease.

Abbott Completes Acquisition of Cardiovascular Systems, Inc.

Abbott's business looks to be returning to normal, and that could be a challenge. The company isn't generating huge numbers from COVID tests anymore.

Why Abbott Laboratories Stock Looks Ridiculously Overpriced

McKesson

Danaher

Eli Lilly

Moderna

UnitedHealth Group

Healthcare stocks are one of the best bets out there. The U.S. spends more on healthcare than any other country.

7 Healthcare Stocks With Huge Return Potential for Long-Term Investors

Automatic Data Processing

Ecolab

Essex Property Trust

Hormel Foods

Nordson

Sherwin-Williams

S&P Global

Stanley Black & Decker

Sysco

T. Rowe Price Group

V.F.

NOBL mustered a comeback in March finishing the month up 0.99%, the ETF is up 1.79% after Q1 2023. Q2 is off to a good start as NOBL is up 1.52% through April 25th.

My Best Dividend Aristocrats For May 2023

NEW YORK , April 25, 2023 /PRNewswire/ -- Cytek Biosciences Inc (NASD:CTKB) will replace Cardiovascular Systems Inc. (NASD:CSII) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, May 1. S&P 500 and 100 constituent Abbott Laboratories (NYSE:ABT) is acquiring Cardiovascular Systems in a deal expected to be completed soon, pending final closing conditions.

Cytek Biosciences Set to Join S&P SmallCap 600

NuVasive

Investors looking for stocks in the Medical - Products sector might want to consider either NuVasive (NUVA) or Abbott (ABT). But which of these two stocks is more attractive to value investors?

NUVA vs. ABT: Which Stock Is the Better Value Option?

Apple

It takes rock-solid cash flows to pay a rock-solid dividend for years on end. Abbott Labs is a key supplier of all kind of medical products to the healthcare sector.

Sleep Easy With These 2 Rock-Solid Dividend Stocks

Abbott's CentriMag™ Blood Pump, previously cleared for use up to six hours, now can be used to provide longer-term life support to critically ill patients, providing doctors more time to make critical care decisions Abbott's CentriMag™ Pre-connected Pack, which combines a blood pump and oxygenator to form a life support circuit, also received FDA clearance for life support lasting less than six hours, helping physicians provide urgent critical care more efficiently and in fewer steps ABBOTT PARK, Ill., April 25, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced two new clearances from the U.S. Food and Drug Administration (FDA) for the company's industry-leading life support system.

Abbott's Life Support System Receives New FDA Clearances to Help Doctors Treat More Critically Ill Patients

News for Abbott Labs Stock (ABT)